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INTRODUCTION
Tuberculosis (TB) is the world’s leading cause of death from
a single infectious disease, and despite advances in chemothe-
rapy policy, the prevalence of TB remains high. Furthermore,
resistance to anti-TB drugs is an increasing problem in many
parts of the world, and the identification of the drug-resis-
tance rate and risk factors is critical for controlling drug-resis-
tant TB (1). Patients with multidrug-resistant TB (MDR-
TB) are difficult to cure, and treatment is much more toxic
and expensive (2-6).
In Korea, TB remains a major public health threat and an
economic burden. Official data reported 35,269 new cases
(73.0/100,000 population) in 2005 (7). In Korea, a complex
cooperative relationship exists between the public and pri-
vate sectors in the treatment of TB (8). The public sector is
composed of approximately 250 National Tuberculosis Pro-
gram (NTP) health centers and two national TB hospitals.
The private sector includes a wide variety of physicians, rang-
ing from general practitioners in private practice to pulmo-
nary specialists at referral hospitals. 
Previous studies of drug-resistant TB in Korea have been
conducted mainly in the public sector (9-12), where accord-
ing to the results of a recent national survey, MDR-TB strains
occurred in 2.7% of new cases and 14.0% of previously treat-
ed cases (12). However, few data have been collected regard-
ing the drug resistance of Mycobacterium tuberculosis in the pri-
vate sector, where at least two-thirds of TB patients in Korea
were treated (7). 
The goals of this study were to identify first-line anti-TB
drug resistance in new and previously treated patients and
to determine the risk factors for MDR-TB at a private refer-
ral center in Korea.
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Drug Resistance Rates of Mycobacterium tuberculosis at a Private
Referral Center in Korea
The goals of this study were to identify first-line drug resistance in new and previ-
ously treated tuberculosis (TB) cases and to determine risk factors for multidrug-
resistant TB (MDR-TB) at a private referral center in Korea. All patients with culture-
confirmed pulmonary TB over a 2-yr period between July 2002 and June 2004 were
prospectively included in this study. In total, 637 patients were included; 512 (80.4%)
were new cases, and 125 (19.6%) were previously treated cases. Resistance to at
least one first-line drug was identified in 11.7% of new cases and 41.6% of previ-
ously treated cases. MDR-TB was detected in 3.9% of new cases and 27.2% of
previously treated cases. The proportion of extensively drug-resistant TB among
MDR-TB patients was 16.7% (9/54). Factors associated with MDR-TB included
age under 45 yr, previous TB treatment, and the presence of cavitation on chest
radiography. Rates of first-line drug resistance are high, particularly in previously
treated patients, in the private sector in Korea. This underscores the need for an
improved control program, coupled with early diagnosis of MDR-TB, to reduce the
spread and development of resistance.
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MATERIALS AND METHODS 
Patients 
All patients with culture-confirmed pulmonary TB diag-
nosed at the Samsung Medical Center (a 1,250-bed referral
hospital in Seoul, Korea) over a 2-yr period between July 2002
and June 2004 were prospectively included in this study. Dur-
ing the 2-yr study period, M. tuberculosis was isolated from
743 patients. Of these, 106 were excluded from this study:
the patients who had already started treatment for TB before
the beginning of the study period (n=29), pediatric patients
who were less than 15 yr of age (n=7), and extrapulmonary
TB cases (n=70). Thus, 637 patients with culture-confirmed
pulmonary TB were included in this study. 
Laboratory methods 
Clinical specimens were stained using the Ziehl-Neelsen
method (13). The results of sputum smear on microscopy
were reported semiquantitatively, and a positive smear was
defined as one with more than one acid-fast bacillus (AFB)
per 100 in a field under high-power (13). Clinical specimens
were cultured on 3% Ogawa medium. The identity of M.
tuberculosis cultures was confirmed using a combination of
growth rate, colony morphology, and pigmentation, and
with the aid of a commercial DNA probe (Gen-Probe Am-
plified Mycobacterium Tuberculosis Direct Test; Gen-Probe
Inc. San Diego, CA, U.S.A.). All isolates of M. tuberculosis
were referred to the Korean Institute of Tuberculosis for drug
susceptibility testing. When multiple isolates were obtained
from the same patient, only the first isolate was used in this
study.
The drug susceptibility of the M. tuberculosis isolates was
determined by the absolute concentration method, using
Lowenstein-Jensen medium (9). The drugs and their critical
concentrations for resistance were as follows: isoniazid (INH),
0.2  g/mL; rifampin (RFP), 40  g/mL; streptomycin (SM),
10  g/mL; and ethambutol (EMB), 2  g/mL. Pyrazinamide
(PZA) susceptibility was determined by a pyrazinamidase test.
Definitions
Patients were classified into two groups according to their
treatment history at the time of diagnosis: new cases, which
included patients who had never received anti-TB treatment
or who had received treatment for <4 weeks, and previously
treated cases, which included patients who had taken anti-
TB drugs for at least 4 weeks (14).
Initial resistance was defined as the presence of drug-resis-
tant M. tuberculosis strains in new cases. Acquired resistance
was defined as the presence of drug-resistant M. tuberculosis
strains in patients who were reported to have received anti-
TB treatment for >4 weeks. Any drug resistance was defined
as resistance to any drug. Monoresistance was defined as resis-
tance to only one of the five first-line drugs (INH, RFP, PZA,
SM, and EMB). MDR was defined as resistance to at least
INH and RFP. 
MDR-TB cases were further analyzed to determine the ex-
tent of drug resistance. Extensively drug-resistant TB (XDR-
TB) was defined as resistance to at least RFP and INH (which
is MDR-TB by definition), in addition to any fluoroquino-
lone, and to at least one of the three following injectable
drugs used in anti-TB treatment: capreomycin, kanamycin,
and amikacin (15). The second-line drugs and their critical
concentrations for resistance were as follows: kanamycin 40
g/mL; capreomycin 40  g/mL; prothionamide 40  g/mL;
cycloserine 30  g/mL; para-aminosalicylic acid 1.0  g/mL;
and ofloxacin 2.0  g/mL.
Statistical analysis
The overall results are expressed as percentages and abso-
lute frequencies for qualitative variables and as mean results
for quantitative variables. We compared the clinical and radio-
graphic findings between patients with MDR-TB and those
with non-MDR-TB. Frequencies were analyzed using the
chi-square test or the Fisher’s exact test, as appropriate. Mul-
tivariate analysis was conducted with a logistic regression
model to determine independent risk factors for MDR-TB.
A p value of less than 0.05 was considered significant. Cal-
culations were performed using the SPSS statistical program
(SPSS version 10.0; SPSS Inc. Chicago, IL, U.S.A.). 
RESULTS
Characteristics of patients
In total, 637 patients newly diagnosed with pulmonary TB
between July 2002 and June 2004 were included. Of the 637
patients, 512 (80.4%) were new cases and 125 (19.6%) were
previously treated cases. The mean age of the patients was 48
yr (range, 15-92 yr), and 372 (58%) were male (Table 1). 
Drug resistance of M. tuberculosis 
Of the M. tuberculosis strains isolated from the 637 patients,
TB, tuberculosis; AFB, acid-fast bacilli.
Mean age, years (range) 48 (15-92)
Male patients 373 (58.4%)
Previous TB treatment 125 (19.6%)
Cavitation on chest radiography 182 (28.6%)
Diabetes mellitus 87 (13.7%)
Positive sputum AFB smear 397 (62.3%)
Table 1. Characteristics of the study population (n=637)TB Drug Resistance at a Private Referral Center in Korea 679
525 (82.4%) were susceptible to all first-line drugs tested,
and 112 (17.6%) were resistant to at least one drug. The differ-
ent resistance profiles of the patients are shown in Table 2.
According to the previous treatment status, isolates from
452 (88.3%) of the 512 new cases were susceptible to all first-
line drugs, whereas this percentage was 58.4% for previous-
ly treated patients (73/125). Fifty-four strains from new cases
and 50 from previously treated patients were resistant to INH
(10.5% and 40.0%, respectively). Twenty cases of MDR-TB
were observed among new patients (3.9%) and 34 among
previously treated patients (27.2%). Nine patients (16.7%,
9/54) with MDR-TB were XDR-TB. 
Risk factor analysis of patients with MDR-TB
Patients with MDR-TB (61%) were more likely to be
under 45 yr of age than non-MDR-TB patients (44%; p=
0.008). MDR-TB cases (63.0%) were also more likely to
have received previous TB treatment than non-MDR-TB
(15.6%) cases (p<0.001). In addition, patients with MDR-
TB were more likely to have had a higher percentage of spu-
tum smear results that were positive for AFB (81.5%) and
to have exhibited cavitation on chest radiography (66.7%)
compared to patients with non-MDR-TB (60.4% and 25.0
%, respectively; p=0.002 and p<0.001, respectively).
Multivariate analysis showed that a younger age (<45 yr
old; OR, 2.2; 95% CI, 1.10-4.30; p=0.026), previous TB
treatment (OR, 6.9; 95% CI, 3.61-13.12; p<0.001), and
presence of cavitation on chest radiography (OR, 3.9; 95%
CI, 1.98-7.55; p<0.001) were significant independent risk
factors for MDR-TB (Table 3).
DISCUSSION
The objective of this study, which consecutively enrolled
all patients with newly diagnosed culture-confirmed pulmo-
nary TB during a 2-yr study period, was to identify first-line
drug resistance in the new and previously treated patients
and to determine risk factors for MDR-TB at a private refer-
ral hospital in Korea. The major findings in this study were
the followings. The rate of MDR-TB in the private referral
hospital was high, especially for the previously treated cases.
In addition, age under 45 yr, previous TB treatment, and pres-
ence of cavitation were independent risk factors for MDR-TB.
Knowing the true drug resistance rates in a region or coun-
try is essential for developing appropriate treatment strate-
gies. According to the results of a recent national survey in
Korea, the percentage of MDR strains was 2.7% in new cases
and 14.0% in previously treated cases (12). However, this
survey was conducted only in TB patients who had been
treated in the public sector. In Korea, the number of TB cases
treated in the private sector has been continuously increas-
ing. In the last Nationwide Tuberculosis Prevalence Survey
from 1995, 53% of patients were reported to have received
INH, isoniazid; RFP, rifampicin; PZA, pyrazinamide; SM, streptomycin;
EMB, ethambutol.
New cases
Previously treated 
cases
Total strains tested 512 125
All susceptible 452 (88.3%) 73 (58.4%)
Any drug resistance 60 (11.7%) 52 (41.6%)
INH 54 (10.5%) 50 (40.0%)
RFP 21 (4.1%) 35 (28.0%)
PZA 11 (2.1%) 26 (20.8%)
EMB 22 (4.3%) 26 (20.8%)
SM 13 (2.5%) 10 (8.0%)
Monoresistance 29 (5.7%) 15 (12.0%)
INH 24 (4.7%) 13 (10.4%)
RFP 1 (0.2%) 1 (0.8%)
PZA 0 0
EMB 0 0
SM 4 (0.8%) 1 (0.8%)
Multidrug resistance 20 (3.9%) 34 (27.2%)
INH+RFP 3 (0.6%) 6 (4.8%)
INH+RFP+PZA 0 3 (2.4%)
INH+RFP+PZA+SM 0 1 (0.8%)
INH+RFP+PZA+EMB 9 (1.8%) 13 (10.4%)
INH+RFP+PZA+SM+EMB 1 (0.2%) 6 (4.8%)
INH+RFP+SM 0 1 (0.8%)
INH+RFP+EMB 5 (1.0%) 3 (2.4%)
INH+RFP+SM+EMB 2 (0.4%) 1 (0.8%)
Extensively drug resistance 4 (0.8%) 5 (4.0%)
Table 2. Resistance to first-line drugs among Mycobacterium
tuberculosis strains
Variable
Non-MDR
(n=583)
MDR
(n=54)
Univariate analysis
Multiple logistic regression analysis
OR (95% CI) p value
Age <45 yr 258 (44.3%) 33 (61.1%) 0.008 2.2 (1.10-4.30) 0.026
Male gender 341 (58.5%) 31 (57.4%) 0.444 1.4 (0.73-2.75) 0.299
Previous TB treatment 91 (15.6%) 34 (63.0%) <0.001 6.9 (3.61-13.12) <0.001
Diabetes mellitus 78 (14.9%) 9 (18.4%) 0.516 1.4 (0.57-3.37) 0.469
Positive sputum AFB smear 352 (60.4%) 44 (81.5%) 0.002 1.2 (0.53-2.58) 0.691
Cavitation on chest radiograph 146 (25.0%) 36 (66.7%) <0.001 3.9 (1.98-7.55) <0.001
Table 3. Variables associated with multidrug-resistant tuberculosis
MDR, multidrug-resistant; OR, odds ratio; 95% CI, 95% confidence interval; TB, tuberculosis; AFB, acid-fast bacilli.treatment in NTP health centers and 47% in the private
sector (16). By contrast, 66% of patients with TB were treat-
ed in the private sector and 34% in the NTP health centers
in recent years (7). Therefore, it is imperative to evaluate the
drug resistance rate of M. tuberculosis in the private sector in
Korea. 
In Korea, a few small retrospective studies on the drug resis-
tance of M. tuberculosis have been conducted in the private
sector, reporting rates of MDR-TB up to 7.0% in new patients
and 38.1% in previously treated patients (17-20). Previous
studies had several limitations. First, the drug susceptibility
test was not recommended to new cases by the NTP program
in Korea until recent years. Therefore, the retrospective study
of patients who had drug susceptibility test results could over-
estimate the drug resistance rates. Second, prevalence surveys
of TB may overrepresent cases with longer duration of posi-
tive culture results, thereby overrepresenting patients with
MDR-TB, because MDR-TB tends to be associated with a
longer duration of positive culture results than drug-suscep-
tible TB. 
This prospective study over a 2-yr period included newly
diagnosed cases of pulmonary TB, excluding prevalent cases.
In our study, the rate of primary resistance to any drugs and
the rate of MDR-TB in new patients were 11.7% and 3.9%,
respectively. These initial resistance figures are similar to the
mean figures in the public sector (12.8% and 2.7%, respec-
tively) (12). By contrast, the rate of acquired resistance to any
drug and the rate of MDR-TB in previously treated patients
in our study were 41.6% and 27.2%, respectively. These val-
ues are significantly higher than those reported in the pub-
lic sector (27.7% and 14.0%, respectively) (12). These differ-
ences could be explained by the higher proportion of treat-
ment failure cases among previously treated patients in pri-
vate tertiary referral hospitals, while the majority of previous-
ly treated patients in public sector are cases of relapse due to
drug-susceptible bacilli (8). 
This study demonstrated that 16.7% (9/54) of MDR-TB
cases were XDR-TB. In March 2006, a report from the US
Centers for Disease Control and Prevention (CDC) and the
World Health Organization (WHO) drew international
attention to the emergence of XDR-TB (21). In this report,
XDR-TB was defined as resistance to at least three of the
six classes of available second-line drugs (aminoglycosides,
polypeptides, fluoroquinolones, thioamides, cycloserine,
and para-aminosalicylic acid) in addition to MDR-TB (21).
The proportion with XDR-TB among MDR-TB cases in
Korea was 15.4% in this report (21). Recently, WHO revised
laboratory case definition for XDR-TB. XDR-TB was de-
fined as resistance to at least RFP and INH, in addition to
any fluoroquinolone, and to at least one of the three follow-
ing injectable drugs used in anti-TB treatment: capreomy-
cin, kanamycin, and amikacin (15). The proportion of XDR-
TB among MDR-TB cases in our study (16.7%) was simi-
lar to that in the previous report (15.4%) (21), although the
definition of XDR-TB has been changed.
In addition, our study found that previous history of TB
treatment, younger age (<45 yr old), and presence of cavita-
tion on radiography were significant risk factors for MDR-
TB. In line with other reports (22-24), previous TB treat-
ment was the strongest risk factor for MDR-TB in our study
(OR, 6.9; 95% CI, 3.61-13.12).
An association was observed between MDR-TB and age
under 45 yr, as has been noted in previous studies (24-26).
This result could reflect the year in which effective anti-TB
drugs such as RFP were introduced. In Korea, RFP-based
regimens were first applied in the private sector during the
1980s, and the current 6-month, four-drug regimen became
standard in the NTP in 1990. Elderly patients have acquired
the organisms in the past, when the circulating bacilli were
susceptible, whereas young patients have acquired the bacilli
more recently, when the bacilli were more likely to be resis-
tant.
The presence of cavitation on chest radiography was also
an independent risk factor for MDR-TB in our study. Altho-
ugh some previous studies suggest that cavitation on chest
radiography is a risk factor for MDR-TB (27, 28), a possible
explanation is still elusive.
This study has several limitations. Among those with pre-
vious TB treatment, a lack of information on the suscepti-
bility of the isolate from the initial TB episode precluded
ascertaining whether drug resistance was attributable to inad-
equate or incomplete treatment, or was the results of prima-
ry infection with a resistant strain. In addition, the potential
association between drug resistance and treatment length
could not be examined, as the timing and duration of previ-
ous treatments were not well documented in the patients’
medical records or recollected by patients (29).
In summary, the drug-resistance rate of pulmonary TB,
especially MDR-TB, is higher in the previously treated pa-
tients at a private referral hospital than in those in the pub-
lic sector in Korea. Younger age (<45 yr old), previous TB
treatment, and the presence of cavitation on chest radiogra-
phy were independent risk factors of MDR-TB. In addition,
a significant proportion of MDR-TB cases was XDR-TB. This
underscores the need for an improved control program, cou-
pled with early diagnosis of MDR-TB, in the private sector
in Korea, especially in high-risk patients, to reduce the spread
and development of resistance.
REFERENCES
1. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori
GB, Baez J, Kochi A, Dye C, Raviglione MC. Standard short-course
chemotherapy for drug-resistant tuberculosis: treatment outcomes
in 6 countries. JAMA 2000; 283: 2537-45.
2. Colebunders R, Apers L, Shamputa IC. Treatment of multidrug-resis-
tant tuberculosis. Lancet 2004; 363: 1240.
680 J.C. Choi, S.Y. Lim, G.Y. Suh, et al.3. Timperi R, Han LL, Sloutsky A, Becerra MC, Nardell EA, Salazar
JJ, Smith-Fawzi MC. Drug resistance profiles of Mycobacterium
tuberculosis isolates: five years’ experience and insight into treat-
ment strategies for MDR-TB in Lima, Peru. Int J Tuberc Lung Dis
2005; 9: 175-80.
4. Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S,
Casali L, Fiorentini F, Codecasa LR, Migliori GB. Management of
multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis 2005;
9: 507-13.
5. Torun T, Gungor G, Ozmen I, Bolukbasi Y, Maden E, Bicakci B,
Atac G, Sevim T, Tahaoglu K. Side effects associated with the treat-
ment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;
9: 1373-7.
6. Kang YA, Choi YJ, Cho YJ, Lee SM, Yoo CG, Kim YW, Han SK,
Shim YS, Yim JJ. Cost of treatment for multidrug-resistant tubercu-
losis in South Korea. Respirology 2006; 11: 793-8.
7. Korean Center for Disease Control and Prevention. Annual report on
the notified tuberculosis patients in Korea (2005.1-2005.12). 2006.
8. Seung KJ, Bai GH, Kim SJ, Lew WJ, Park SK, Kim JY. The treat-
ment of tuberculosis in South Korea. Int J Tuberc Lung Dis 2003; 7:
912-9.
9. Kim SJ, Bai GH, Hong YP. Drug-resistant tuberculosis in Korea,
1994. Int J Tuberc Lung Dis 1997; 1: 302-8.
10. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL,
Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chau-
let P, Nunn P. Global surveillance for antituberculosis-drug resis-
tance, 1994-1997. World Health Organization-International Union
against Tuberculosis and Lung Disease Working Group on Anti-Tu-
berculosis Drug Resistance Surveillance. N Engl J Med 1998; 338:
1641-9.
11. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero
A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione
MC. Global trends in resistance to antituberculosis drugs. World
Health Organization-International Union against Tuberculosis and
Lung Disease Working Group on Anti-Tuberculosis Drug Resistance
Surveillance. N Engl J Med 2001; 344: 1294-303.
12. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK,
Kim SJ. Trend of anti-tuberculosis drug resistance in Korea, 1994-
2004. Int J Tuberc Lung Dis 2007; 11: 571-6.
13. American Thoracic Society. Diagnostic standards and classification
of tuberculosis in adults and children. Am J Respir Crit Care Med
2000; 161: 1376-95.
14. World Health Organization. Treatment of tuberculosis: guidelines
for national programmes 2003.
15. World Health Organization. Report of the meeting of the WHO Glob-
al Task Force on XDR-TB. 2006.
16. Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nation-
wide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc
Lung Dis 1998; 2: 27-36.
17. Kim JH, Kim JH, Jang TW, Jung MH. Drug-resistant pulmonary
tuberculosis in Kosin Medical Center. Tuber Respir Dis 1995; 42:
831-7.
18. Kim SY, Jeong SS, Kim KW, Shin KS, Park SG, Kim AK, Cho HJ,
Kim JO. Drug-resistant pulmonary tuberculosis in a tertiary refer-
ral hospital in Korea. Korean J Intern Med 1999; 14: 27-31.
19. Lee JH, Chang JH. Drug-resistant tuberculosis in a tertiary referral
teaching hospital of Korea. Korean J Intern Med 2001; 16: 173-9.
20. Kim DK, Kim MO, Kim TH, Sohn JW, Yoon HJ, Shin DH, Park SS.
The prevalence and risk factors of drug resistance pulmonary tuber-
culosis investigated at one university hospital in Seoul. Tuber Respir
Dis 2005; 58: 243-7.
21. Centers for Disease Control and Prevention. Emergence of Mycobac-
terium tuberculosis with extensive resistance to second-line drugs--
worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:
301-5.
22. Arevalo M, Solera J, Cebrian D, Bartolome J, Robles P. Risk factors
associated with drug-resistant Mycobacterium tuberculosis in Castil-
la-la-Mancha (Spain). Eur Respir J 1996; 9: 274-8.
23. Ruddy M, Balabanova Y, Graham C, Fedorin I, Malomanova N,
Elisarova E, Kuznetznov S, Gusarova G, Zakharova S, Melentyev
A, Krukova E, Golishevskaya V, Erokhin V, Dorozhkova I, Drob-
niewski F. Rates of drug resistance and risk factor analysis in civil-
ian and prison patients with tuberculosis in Samara Region, Russia.
Thorax 2005; 60: 130-5.
24. Faustini A, Hall AJ, Perucci CA. Risk factors for multi-drug resis-
tant tuberculosis in Europe: a systematic review. Thorax 2006; 61:
158-63. 
25. Djuretic T, Herbert J, Drobniewski F, Yates M, Smith EG, Magee
JG, Williams R, Flanagan P, Watt B, Rayner A, Crowe M, Chadwick
MV, Middleton AM, Watson JM. Antibiotic resistant tuberculosis
in the United Kingdom: 1993-1999. Thorax 2002; 57: 477-82.
26. Kordy FN, Al-Thawadi S, Alrajhi AA. Drug resistance patterns of
Mycobacterium tuberculosis in Riyadh, Saudi Arabia. Int J Tuberc
Lung Dis 2004; 8: 1007-11.
27. Harrow EM, Rangel JM, Arriega JM, Cohen I, Regil Ruiz MI, De-
Riemer K, Small PM. Epidemiology and clinical consequences of
drug-resistant tuberculosis in a Guatemalan hospital. Chest 1998;
113: 1452-8.
28. Sharma SK, Turaga KK, Balamurugan A, Saha PK, Pandey RM,
Jain NK, Katoch VM, Mehra NK. Clinical and genetic risk factors
for the development of multi-drug resistant tuberculosis in non-HIV
infected patients at a tertiary care center in India: a case-control
study. Infect Genet Evol 2003; 3: 183-8.
29. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE,
Smith I, Suarez P, Antunes ML, George AG, Martin-Casabona N,
Simelane P, Weyer K, Binkin N, Raviglione MC. Determinants of
drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc
Lung Dis 2001; 5: 887-93.
TB Drug Resistance at a Private Referral Center in Korea 681